Race Receives Positive Guidance on Zantrene via Pre-IND Meeting with US FDA

Race Develops Improved IV Formulation of Zantrene
Race-Develops-Improved-IV-Formulation-of-ZantreneDownload To discuss or comment on this announcement please visit our Investor Hub.
Race secures fifth US patent for Zantrene
Race Oncology (“Race”) is pleased to announce that it has been issued a new patent…
Race secures sixth US patent for Zantrene
United States Patent No. 11,147,800 entitled COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE…